Theriva Biologics, Inc. (NYSEAMERICAN:TOVX – Get Free Report) shares were up 4.5% during mid-day trading on Tuesday . The company traded as high as $0.44 and last traded at $0.42. Approximately 50,772 shares were traded during trading, a decline of 56% from the average daily volume of 114,650 shares. The stock had previously closed at $0.40.
Theriva Biologics Trading Up 4.5 %
The company has a market cap of $7.22 million, a P/E ratio of -0.36 and a beta of 1.48.
Theriva Biologics (NYSEAMERICAN:TOVX – Get Free Report) last posted its quarterly earnings results on Monday, March 25th. The company reported ($0.32) EPS for the quarter.
About Theriva Biologics
Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.
Featured Stories
- Five stocks we like better than Theriva Biologics
- Business Services Stocks Investing
- Garmin Navigates to New Highs Driven By Wearables Trend
- Most Volatile Stocks, What Investors Need to Know
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- Energy and Oil Stocks Explained
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for Theriva Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theriva Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
